Objective-We evaluated the safety of coronary reactivity testing (CRT) in symptomatic women with evidence of myocardial ischemia and no obstructive coronary artery disease (CAD).
Introduction
In patients undergoing angiography for stable angina, the proportion of women and men with no obstructive CAD is increasing over time (1) . Compared to men, women have a higher incidence of signs and symptoms of myocardial ischemia, yet 30-50% of women who undergo coronary angiography do not have obstructive coronary artery disease (CAD) (2) (3) (4) . The absence of obstructive CAD is not benign, as 38% of women with acute myocardial infarction (MI) and no obstructive CAD have been found to have plaque rupture or ulceration using intravascular ultrasound (5) . Women with angina in the absence of obstructive CAD are often inappropriately reassured and even dismissed without further investigation or treatment: yet angina among women regardless of coronary angiographic findings is associated with increased mortality (6) (7) . The National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women's Ischemia Syndrome Evaluation (WISE) studies have documented that approximately half of these symptomatic women with no obstructive CAD have microvascular coronary dysfunction (MCD), which produces ischemia and is associated with an adverse cardiovascular prognosis compared to asymptomatic women (3) (4) (8) (9) (10) (11) . Both coronary artery spasm and endothelial dysfunction have been shown to be predictors of morbidity and mortality in patients with angina (12) (13) (14) (15) (16) . Coronary spasm may result in MI, ventricular arrhythmias and sudden cardiac death (15, (17) (18) . Recent data show that women without obstructive CAD who have a low coronary flow reserve (CFR) are at higher risk of major adverse cardiac events (MACE) compared to those with normal CFR (19) . Treatment directed at endothelial function can reduce angina, coronary spasm, heart failure, and stroke (20) (21) (22) (23) ; therefore, it is important to establish the diagnosis in order to institute appropriate medical management.
Invasive coronary reactivity testing (CRT) using vasoactive agents to evaluate macroand microvascular responses is considered the reference-standard for a definitive diagnosis of MCD (24) . However, it is not routinely performed for a variety of reasons, including lack of standardized protocols and concerns over catheterization laboratory time. Furthermore, limited data exist on the safety of contemporary CRT in women suspected of having MCD. We evaluated the safety of CRT performed at three experienced centers in women with angina, evidence of myocardial ischemia by stress testing, and no obstructive CAD (3, 25) .
Methods
Women with angina and evidence of myocardial ischemia underwent CRT at three experienced clinical centers that participate in WISE: the University of Pittsburgh, the University of Florida, Gainesville, and Cedars-Sinai Medical Center. Inclusion criteria:
women with angina, myocardial ischemia by stress testing, absence of obstructive CAD (<50% luminal obstruction in one or more epicardial coronary arteries on angiography). Exclusion criteria: contraindications to angiography and invasive CRT (hypersensitivity of contrast media, active bleeding, bleeding diathesis, renal dysfunction), prior or planned percutaneous coronary intervention or coronary artery bypass grafting, acute MI within 30 days, primary valvular heart disease, cardiogenic shock or intra-aortic balloon pump, inability to withhold nitrates, calcium channel agents, and alpha and beta adrenergic blockers for 24 hours prior to testing, New York Heart Association class III or IV heart failure, ejection fraction <40%, hypertrophic obstructive cardiomyopathy, severe lung, renal, or hepatic disease, life expectancy <6 months, age <21 years, or pregnancy. All study participants gave written informed consent before undergoing evaluation. Demographic data were recorded with standardized questionnaires. CRT data were read on site (at the CedarsSinai Cardiovascular Intervention Center) or at the WISE Angiographic Core Laboratory (Brown University). The institutional review boards at each site approved the study.
CRT Protocol
Patients fasted for 12 hours and withheld caffeine, long-acting nitrates, and other vasoactive agents for 24 hours prior to testing. Patients were instructed to discontinue nicotine and avoid sublingual nitroglycerin four hours prior to the procedure. Pre-mixed acetylcholine in three concentrations (0.182 mcg/ml, 1.82 mcg/ml, and 18.2 mcg/ml) were prepared within three hours of scheduled procedure.
Outpatient diagnostic coronary angiography was performed via the percutaneous femoral approach. A pigtail catheter measured aortic and left ventricular pressures. Patients with significant CAD, coronary artery anomalies, or bridging were excluded. For borderline lesions, at the discretion of the interventionalist, intravascular ultrasound and/or fractional flow reserve were used to confirm absence of obstructive stenosis.
Following angiography, women were given body-weight adjusted heparin for anticoagulation and ACT was maintained above 250. CRT was performed by infusing vasoactive substances through a guiding catheter placed in the left main coronary artery. Doppler guide wire (0.014-in diameter, FloWire, JOMED/Cardiometrics/Volcano) was positioned in the proximal left anterior descending coronary artery. The following coronary functions were tested:
A. Non-endothelial dependent microvascular function determination: After an adequate flow reading was obtained by the ComboMap Pressure and Flow System (JOMED/Cardiometrics/Volcano), baseline average peak velocity was recorded. Intracoronary (IC) bolus injections of incremental doses of adenosine (18 mcg, 18mcg and 36 mcg) were administered to create maximal hyperemia. The catheter was flushed with saline after each adenosine injection, and an average peak velocity reading was obtained five seconds after the saline flush. Adenosine CFR was calculated by ComboMap as a ratio of average peak velocity to average baseline velocity. This process was repeated and recorded for each dose of adenosine after the peak velocity returned to baseline. A CFR ≤2.5 in response to adenosine was considered abnormal (14, 19) .
B. Endothelial-dependent micro-and macro-vascular dysfunction determination:
Graded IC acetylcholine concentrations of 0.182 mcg/ml and 18.2 mcg/ml were infused (2 ml over 3 minutes). An intermediate dose of 1.82 mcg/ml was infused at the discretion of the angiographer if it was deemed unsafe to proceed directly to a higher dose of 18.2 mcg/ml, based on the coronary reactivity from the lower dose (i.e., 0.182 mcg/ml) of acetylcholine. Doppler measurement of peak velocity was obtained at the end of each acetylcholine infusion. Normal endothelial-dependent microvascular response was defined as a coronary blood flow increase >50% at the highest dose of acetylcholine. Post-acetylcholine cine image was obtained for each concentration for quantitative coronary angiography (QCA). We ensured that coronary flow returned to baseline prior to each infusion. Normal acetylcholine response, or endothelialdependent macrovascular coronary function, was defined as coronary artery dilation >5%. Coronary blood flow response to acetylcholine was calculated from the Doppler-derived time velocity integral and vessel diameter by the following equation: Coronary blood flow = π (average peak velocity/2)(vessel diameter/2) 2 . Vessel diameter was calculated 5 mm distal to the Doppler wire.
C. Non-endothelial-dependent macrovascular function determination: After completion of acetylcholine infusions and the return of coronary flow velocity to baseline, IC nitroglycerin (200 mcg) was injected to evaluate non-endothelialdependent macrovascular function. Average baseline and peak velocity were recorded. A cine image within 30 seconds of IC nitroglycerin was obtained for QCA. Normal nitroglycerin response was defined as a diameter increase >20%.
The angles, skew rotation, and table height were kept constant during the procedure. QCA measurements were made in the segment 5mm distal to the tip of the Doppler wire. For each time interval, the diameter was measured in the same segment. Heart rate and blood pressure were recorded before and after administration of adenosine, acetylcholine, and nitroglycerin.
Peri-procedural Adverse Events
Adverse events (AE) and serious adverse events (SAEs) during and immediately post-CRT were recorded. SAEs were defined as those that required termination of the protocol and immediate hospitalization (hemodynamic instability, coronary artery dissection, myocardial infarction, stroke, and death). AEs were defined as events related to the procedure which did not require hospitalization (such as deep venous thrombosis, transient coronary air embolism, nonsustained arrhythmias, and transient hypotension not requiring treatment). SAEs and AEs were adjudicated by a clinical events committee.
Outcomes during Follow-up
As per WISE protocol, women were followed 6 weeks and then annually for death, nonfatal MI, non-fatal stroke, and hospitalization for heart failure. MACE rate was calculated as the percentage of patients with a first event.
Results
The patient demographics are shown in Table 1 . Results of CRT are reported in Table 2 ; not all patients underwent all aspects of reactivity testing, as this was site-dependent. CRT related SAEs occurred in 2 women (0.7 %) and included one coronary artery dissection (0.3%) and one ST-elevation MI due to coronary artery spasm (0.3%) ( Table 3) . CRTrelated AEs occurred in 2 women (0.7 %), and included one with transient air microembolism (0.3%) and one with deep venous thrombosis on the side of the groin access site (0.3%), greater than 30 days after the CRT (Table 4 ). The combined CRT-related AE/ SAE rate was 1.4%. There was no CRT-related mortality.
The prevalence of epicardial coronary vasospasm in our women was 5 %, when vasospasm was defined as acetylcholine response of >50% coronary artery diameter reduction from baseline diameter (26) . When defined as >70% coronary artery diameter reduction to acetylcholine from baseline, vasospasm occurred in 2 patients (0.9%). We also compared acetylcholine response to post-nitroglycerin diameter. 5 patients (2.3%) had a >70% reduction in diameter to acetylcholine compared to post-nitroglycerin diameter.
The cohort was then followed for a period of 5. (28) . Accordingly, establishment of the diagnosis of MCD in these patients is important for appropriate medical management.
Coronary blood flow is regulated by various endothelial-dependent and non-endothelialdependent factors. Non-endothelial-dependent factors include myocardial metabolism, myocardial compressive forces, aortic pressure, and neurohumoral substances (29) . We measured CFR directly by the Doppler wire in response to adenosine, a non-endothelial dependent vasodilator (30) . Acetylcholine was used to test endothelium-dependent function, as it stimulates nitric oxide release from the endothelial cells. Nitroglycerin response was used to test non-endothelial dependent macrovascular function. Procedural success rates were high in our study, and half of patients had an abnormal CRT in our patient population ( Table 2) .
Safety of IC Doppler flow measurement
IC Doppler measurement currently has a class IIb recommendation for assessment of the severity of coronary flow abnormalities in patients with angina, ischemia by stress testing, but no obstructive CAD (31) . The Doppler wire used in our study is a 0.014-inch diameter flexible, steerable guide wire with a piezoelectric ultrasound transducer integrated into the tip (32) (33) . The Doppler wire may cause coronary spasm, which was previously seen in 1% of patients undergoing IC Doppler examination (34) . Wire-induced spasm was relieved by IC nitroglycerin, similar to our contemporary study findings. A smaller study of 44 patients reported that no Doppler wire-related complications occurred in patients with normal or mild CAD (35) . In our study, there was one coronary artery dissection (0.3%) that may be due to the Doppler wire. The dissection likely occurred during placement of the Doppler wire before reactivity testing. Focal vasospasm and staining of the mid left anterior descending artery were then noted during acetylcholine injection. No intervention was needed as the dissection was stable with no limitation of flow.
Safety of IC adenosine
The safety and use of IC boluses of adenosine is well established (36) (37) (38) . In a study of 39 patients by Wilson et al (39) , IC boluses (2-16 mcg) produced small, brief, dose-dependent reductions in mean arterial pressure and did not significantly change the PR, QRS, or QT intervals on the electrocardiogram, even when the drug was injected directly into the right coronary artery. However, in a study by Qian et al (34) of 906 patients, 14 patients experienced arrhythmias (7 asystole, 4 2 nd degree AV block, 1 3 rd degree AV block, 1 severe sinus bradycardia, 1 ventricular fibrillation), all whom received IC bolus of 12 mcg adenosine in the right coronary artery. One patient experienced sinus bradycardia and hypotension after 18 mcg of IC adenosine in the left anterior descending artery after stent implantation (34) . In our study of 293 patients, neither the 18mcg nor the 36mcg dosages of adenosine resulted in any arrhythmias, and all cases were performed in the left coronary artery, showing that contemporary testing safety has improved and is safe.
Safety of IC acetylcholine
Acetylcholine has been used to evaluate coronary vasomotor function. Sueda et al (40) performed 1000 acetylcholine tests in Japanese men with and without obstructive CAD from 1991 to 2004. Incremental doses of 20/50/80 mcg into the right coronary artery and 20/50/100 mcg into the left coronary artery were injected over 20 seconds. They reported 17/1000 patients (1.7%) who experienced a major adverse reaction during acetylcholine infusion, including 11 nonsustained ventricular tachycardia (1.1%), one sustained ventricular tachycardia (0.1%), one ventricular fibrillation (0.1%), 3 shock due to left main stem spasm (0.3%), and one cardiac tamponade (0.1%). No serious complications, such as death, stroke or acute MI, were observed in this study.
More recently, the CASPAR (Coronary Artery Spasm in Patients with Acute Coronary Syndrome) study investigators injected incremental doses of acetylcholine (2/20/100 mcg over 3 minutes) into the left coronary artery and/or right coronary artery of 86 patients (15) . Coronary vasospasm was detected in 42 patients (49%). Ischemic ST-segment changes were seen in 20 patients (17 ST depressions, 3 ST elevation), but there were no clinical adverse events. In a study of nifedipine's effect on endothelial dysfunction, investigators infused acetylcholine (0.36, 3.6, and 18 mcg/ml at 2 mL/min for 3 min) in either the left anterior descending artery or circumflex artery of 641 patients (41) . Transient electrocardiographic changes were reported in 5 patients, while diffuse coronary vasoconstriction with hemodynamic instability occurred in 5 patients (0.78%) (one [0.16 %] which required resuscitation). One patient (0.16%) developed acute coronary syndrome and cardiac arrest in the catheterization laboratory, possibly related to acetylcholine.
In our similarly-sized study, acetylcholine infusions were well tolerated without significant hemodynamic changes, again suggesting that contemporary testing safety has improved. Although some patients did experience chest pain at higher doses of acetylcholine, we were careful in monitoring coronary flow throughout acetylcholine infusion to assess for significant spasm. Five patients (2.3%) developed acetylcholine-induced vasospasm which immediately resolved after nitroglycerin injection, with no further sequelae. The higher doses of acetylcholine used in the CASPAR study (2/20/100 mcg) likely caused more coronary vasospasm than the lower doses of acetylcholine used in our study (0.364/3.64/36.4 mcg). Our case of coronary artery dissection was likely due to the Doppler wire rather than vasospasm from acetylcholine.
Limitations
As per WISE protocol, CRT was performed in the left anterior descending coronary artery in all patients. Safety of CRT in the right coronary artery or left circumflex artery was not evaluated. Acetylcholine is not directly infused into the left anterior descending artery but rather infused through the guiding catheter in the left main coronary artery, and thus the concentration of the acetylcholine may be diluted in the left anterior descending artery. Since vasoactive substances are infused in the left main artery, both the circumflex and the left anterior descending artery are susceptible to vasoconstrictive effects. The protocol stipulated for the Doppler wire to be maintained in the proximal left anterior descending artery. Therefore, the safety of CRT when the Doppler wire is placed more distally is unknown. It is also difficult to accurately perform QCA in distal vessels due to smaller diameter.
Conclusion
In women undergoing CRT for suspected MCD, contemporary testing is relatively safe with a low adverse event rate when using standardized protocols for IC adenosine, acetylcholine, and nitroglycerin delivery in experienced centers. These results support the use of CRT by experienced operators for diagnostic and prognostic purposes in patients with persistent angina, evidence of myocardial ischemia, and no obstructive CAD. Prior studies investigating therapy directed at improvement of MCD have shown reduction of angina, vasospasm, heart failure, and stroke. Additional studies are needed to demonstrate improvement in cardiovascular outcomes. Anticoagulation was initiated as indicated.
LAD= left anterior descending Artery, RCA = right coronary artery
